Moderna Announces the Launch of Global Fellowship Program for Young Researchers Exploring mRNA Medicines
October 06 2021 - 8:30AM
Business Wire
Initiative to support a new generation of
leaders in mRNA therapeutics and vaccine research
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced the
launch of the Moderna Fellowship Program. The goal of the program
is to support the next generation of scientists and healthcare
professionals as they innovate in the field of mRNA research
towards improving patient care and population health.
Prospective fellows may be clinicians and scientists who are
interested in advancing mRNA research and innovation and the
program underpins Moderna’s commitment to supporting independent
research. The fellowship program will select approximately 50
global fellows in the first year with a focus on infectious
diseases. Greg Poland, M.D., infections disease expert and Director
of Mayo Clinic's Vaccine Research Group, will serve as Chair of the
program.
“We’re at a critical moment for mRNA vaccine development,” said
Dr. Poland. “The time is now for investing in talent and idea
generation that will propel a new era for research of mRNA
approaches to infectious disease – and eventually, other
therapeutic areas.”
“At Moderna, we aspire to make a positive impact today and in
the decades to come. We are humbled by the opportunity to help a
new network of collaborators around the world advance mRNA
research,” said Stéphane Bancel, Chief Executive Officer of
Moderna. “This program presents an opportunity for us to build and
scale a new generation of mRNA scientists, researchers and
healthcare professionals to improve quality of care by educating
and advocating for clinical best practices with mRNA vaccines and
therapeutics.”
The fellowship program will be overseen by an independent
steering committee of international experts in science, medicine,
and healthcare. The committee expects to receive applications from
institutions around the world who wish to appoint a fellow in
either clinical medicine, scientific research or another healthcare
related discipline. To learn more, please visit
www.modernatx.com/research-fellowship.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed. Moderna maintains alliances with
a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both
groundbreaking science and rapid scaling of manufacturing. Most
recently, Moderna’s capabilities have come together to allow the
authorized use of one of the earliest and most effective vaccines
against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the Company’s launch of a
global fellowship program for researchers exploring mRNA medicines
and the design and potential impact of that program. The
forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond Moderna’s control and which could cause actual results to
differ materially from those expressed or implied by these
forward-looking statements. These risks, uncertainties, and other
factors include those other risks and uncertainties described under
the heading “Risk Factors” in Moderna’s most recent Annual Report
on Form 10-K filed with the U.S. Securities and Exchange Commission
(SEC) and in subsequent filings made by Moderna with the SEC, which
are available on the SEC’s website at www.sec.gov. Except as
required by law, Moderna disclaims any intention or responsibility
for updating or revising any forward-looking statements contained
in this press release in the event of new information, future
developments or otherwise. These forward-looking statements are
based on Moderna’s current expectations and speak only as of the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211006005341/en/
Media Colleen Hussey Director, Corporate Communications
(617) 335-1374 Colleen.Hussey@modernatx.com Investors Lavina
Talukdar Senior Vice President & Head of Investor Relations
(617) 209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024